A large multinational study examined the potential impact of dapagliflozin on kidney disease in people with type 2 diabetes.
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
More severe frailty predicted a higher risk of UTIs.
Researchers identified lipidomic predictors of rapid decline of kidney function in individuals with type 1 diabetes.
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.
The approval was based on data from the phase 3 FIDELIO-DKD trial.
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
More than one-quarter are classified as rapid decliners, which was more common with type 2 diabetes
Because finerenone inhibits cardiac remodeling in preclinical models, investigators sought to examine its effect on new-onset AFF by analyzing data from the FIDELIO-DKD phase 3 trial.